ABCC13 Antibody

What is ABCC13 and why is it significant in research?

ABCC13 is a member of the ATP-binding cassette (ABC) transporter superfamily, specifically subfamily C. It spans approximately 70kb on human chromosome 21q11.2 and consists of 14 exons encoding a truncated protein of 325 amino acid residues . Unlike other functional ABC transporters, ABCC13 is considered a pseudogene in humans as it lacks key functional motifs typically found in ABC proteins . Its significance lies in its tissue-specific expression pattern, particularly in fetal liver and bone marrow, suggesting a potential role in hematopoiesis . The expression of ABCC13 in K562 cells decreases during cell differentiation induced by TPA, further supporting its connection to hematopoietic development .

Which applications are ABCC13 antibodies most commonly used for?

ABCC13 antibodies are primarily used in the following research applications:

• Western blotting (WB): For detecting endogenous ABCC13 protein in cell and tissue lysates

• Immunohistochemistry (IHC): For visualizing ABCC13 expression in tissue sections

• Immunofluorescence (IF): For subcellular localization studies

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection

Multiple vendors offer ABCC13 antibodies validated for these applications, with most antibodies being suitable for at least WB, IHC, and ELISA applications .

What sample types are most appropriate for ABCC13 antibody detection?

Based on the tissue distribution profile of ABCC13, the most appropriate samples include:

For optimal results in experimental designs, researchers should prioritize samples from tissues with known higher expression levels, particularly when establishing detection protocols .

How should researchers optimize Western blot protocols specifically for ABCC13 detection?

For optimal ABCC13 detection by Western blot, follow these research-validated parameters:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if investigating potential post-translational modifications

• Gel selection:

  • Use 10-12% SDS-PAGE gels for optimal resolution of ABCC13 (~30-35 kDa)

• Antibody dilutions:

  • Primary antibody concentration: 1:500-1:2000 range is recommended

  • Several vendors suggest 1:500 as optimal starting dilution

• Positive controls:

  • HT29 cell lysates have been validated as positive controls

  • 293 cells and HeLa cells also show detectable expression

• Detection system optimization:

  • Enhanced chemiluminescence (ECL) with 2-5 minute exposure typically provides clear bands

  • Avoid excessive stripping if reprobing is necessary as this may reduce ABCC13 signal

Western blot analysis using the recommended conditions should detect endogenous ABCC13 protein as demonstrated in validation data from multiple antibody manufacturers .

What are the key considerations for immunohistochemical detection of ABCC13?

For successful immunohistochemical staining of ABCC13:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Heat-mediated antigen retrieval in citrate buffer (pH 6.0) is crucial

• Antibody optimization:

  • Recommended dilution range: 1:50-1:300

  • Incubation at 4°C overnight typically yields optimal results

  • Use liver carcinoma tissue as positive control

• Detection system:

  • DAB (3,3'-diaminobenzidine) chromogen yields reliable results

  • Hematoxylin counterstaining at 1:4 dilution provides optimal nuclear contrast

• Validation controls:

  • Include antibody omission controls

  • Consider peptide competition assays with ABCC13 neutralizing peptides

  • Lung cancer tissue sections have been validated for positive staining

• Interpretation considerations:

  • ABCC13 typically shows cytoplasmic and membrane staining patterns

  • Compare staining intensity with established positive controls

The specificity of immunohistochemical detection should be verified using neutralizing peptides when available, as many vendors offer matching blocking peptides for their ABCC13 antibodies .

How do polyclonal and monoclonal ABCC13 antibodies compare in research applications?

The choice between polyclonal and monoclonal ABCC13 antibodies depends on specific research objectives:

Polyclonal antibodies like those targeting amino acids 56-105 of ABCC13 have been widely validated across multiple applications , while monoclonal antibodies such as the B-2 clone offer higher specificity for applications requiring precise epitope recognition .

What is the normal tissue distribution pattern of ABCC13 and how should antibody-based detection be interpreted?

ABCC13 exhibits a distinct tissue distribution pattern that researchers should consider when designing and interpreting antibody-based studies:

• Developmental expression:

  • Highest in fetal liver (primary site of expression)

  • Significant in embryonic and fetal hematopoietic tissues

  • Expression decreases during differentiation of hematopoietic cells

• Adult tissue distribution:

  • Predominantly expressed in colon

  • Lower but detectable expression in brain, liver, placenta, lung, ovary, and pancreas

  • Expression in bone marrow but limited in peripheral blood leukocytes

• Interpretation guidelines:

  • Expect stronger staining in fetal tissues compared to adult counterparts

  • Consider developmental stage when analyzing expression patterns

  • Validate antibody detection against established expression profiles

  • Be cautious of potential cross-reactivity with other ABC family members due to sequence similarities

This tissue-specific pattern suggests ABCC13 may have distinct roles during development versus adulthood, particularly in hematopoiesis . Researchers should use appropriate positive controls reflecting this distribution when establishing detection protocols.

How can researchers effectively distinguish between the five known isoforms of ABCC13 using antibodies?

ABCC13 is produced in five isoforms through alternative splicing , presenting challenges for isoform-specific detection. To effectively distinguish between these isoforms:

• Epitope selection strategy:

  • Choose antibodies targeting regions unique to specific isoforms

  • Verify the immunogen sequence against known isoform structures

  • Consider using multiple antibodies targeting different domains

• Western blot analysis:

  • Use high-resolution gels (10-12%) for optimal separation of isoforms based on size differences

  • Include positive controls for each isoform when available

  • Employ gradient gels for improved resolution of closely sized isoforms

• RT-PCR complementation:

  • Combine antibody detection with isoform-specific primers

  • Correlate protein detection with mRNA expression profiles

  • Design primers spanning exon junctions unique to specific isoforms

• Validation approaches:

  • Overexpression systems expressing individual isoforms as reference standards

  • siRNA knockdown targeting isoform-specific regions

  • Mass spectrometry confirmation of antibody-detected bands

• Data interpretation:

  • Document molecular weight variations between isoforms

  • Consider potential post-translational modifications affecting migration patterns

  • Analyze tissue-specific expression patterns of different isoforms

Researchers should be aware that most commercially available antibodies may not explicitly distinguish between all five isoforms unless specifically designed and validated for this purpose.

What are the key considerations when using ABCC13 antibodies in studies of hematopoietic differentiation?

When investigating ABCC13's role in hematopoiesis, researchers should consider:

• Cell model selection:

  • K562 cells show documented ABCC13 expression changes during differentiation

  • Primary CD34+ hematopoietic stem cells provide physiologically relevant models

  • Compare expression across different hematopoietic lineages

• Differentiation protocols:

  • TPA (12-O-tetradecanoylphorbol-13-acetate) induces documented changes in ABCC13 expression

  • Monitor ABCC13 levels at multiple timepoints during differentiation

  • Compare with established hematopoietic differentiation markers

• Antibody application protocols:

  • Flow cytometry: Use permeabilization for this predominantly intracellular protein

  • Immunofluorescence: Co-stain with lineage markers for contextual analysis

  • Western blotting: Include differentiation stage-specific markers for reference

• Experimental controls:

  • Undifferentiated cells as baseline controls

  • Multiple differentiation pathways to assess lineage-specific regulation

  • Positive controls from tissues with known high ABCC13 expression (fetal liver)

• Functional correlation analysis:

  • Correlate ABCC13 expression changes with functional hematopoietic parameters

  • Consider knockdown or overexpression studies to assess causality

  • Analyze relationship between ABCC13 levels and differentiation outcomes

The documented decrease in ABCC13 expression during K562 cell differentiation suggests its potential role as a marker for early hematopoietic stages , making careful antibody validation critical for developmental studies.

How can researchers validate the specificity of ABCC13 antibodies given its pseudogene status?

Given that ABCC13 is considered a pseudogene in humans , validating antibody specificity requires special considerations:

• Recommended validation methods:

  • Peptide competition assays using the specific immunizing peptide

  • Knockdown validation using siRNA or shRNA (despite pseudogene status, transcripts are present)

  • Overexpression studies with tagged ABCC13 constructs

  • Western blot analysis confirming the expected molecular weight (~30-35 kDa)

• Potential cross-reactivity assessment:

  • Test against related ABC transporter family members, particularly those with sequence similarity to ABCC13

  • Include samples from tissues known to be negative for ABCC13

  • Compare signal patterns across multiple antibodies targeting different ABCC13 epitopes

• Technical validation parameters:

  • Signal-to-noise ratio optimization in Western blots

  • Concentration-dependent signal detection

  • Reproducibility across different sample preparation methods

  • Consistency with published expression patterns in tissues

• Additional controls:

  • Use neutralizing peptides specifically designed for the antibody being used

  • Include recombinant protein controls when available

  • Compare detection with antibodies from different sources/clones

The amino acid sequence corresponding to putative membrane-spanning domains shows remarkable similarity to ABCC1, ABCC2, ABCC3, and ABCC6 , making careful validation essential to ensure specificity to ABCC13.

What are the most common technical challenges when working with ABCC13 antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with ABCC13 antibodies:

• Weak or inconsistent signal in Western blots:

  • Solution: Optimize protein loading (25-50 μg recommended)

  • Increase antibody concentration (start with 1:500 dilution)

  • Use enhanced chemiluminescence detection systems

  • Consider longer primary antibody incubation (overnight at 4°C)

• Background issues in immunohistochemistry:

  • Solution: Extend blocking step (1-2 hours with 5% normal serum)

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Increase washing duration and frequency

  • Use more dilute antibody with longer incubation

• Inconsistent results between experiments:

  • Solution: Standardize lysate preparation protocols

  • Use consistent tissue fixation methods

  • Prepare large batches of antibody dilutions to use across experiments

  • Include identical positive controls in each experiment

• Multiple bands in Western blots:

  • Solution: Verify if bands represent known isoforms (five documented isoforms exist)

  • Test with peptide competition to identify specific versus non-specific bands

  • Optimize gel percentage for better resolution

  • Verify sample integrity to rule out degradation products

• Cross-reactivity with other ABC transporters:

  • Solution: Include samples known to express related ABC transporters as controls

  • Use antibodies targeting unique regions of ABCC13

  • Compare results with transcriptional analysis (qPCR)

  • Consider pre-adsorption with related proteins

Careful protocol optimization and inclusion of appropriate controls can address most technical challenges associated with ABCC13 antibody applications.

How should researchers design peptide competition assays to validate ABCC13 antibody specificity?

Peptide competition (blocking) assays are valuable for validating ABCC13 antibody specificity:

• Peptide selection:

  • Use the exact immunizing peptide when available

  • For commercial antibodies, matching blocking peptides are often available from the same vendor

  • Focus on peptides from the region spanning amino acids 56-105, as many antibodies target this region

• Experimental design:

  • Prepare antibody solutions with and without blocking peptide

  • Recommended peptide:antibody molar ratio: 5:1 to 10:1

  • Pre-incubate antibody with peptide for 2 hours at room temperature or overnight at 4°C

  • Run identical samples with blocked and unblocked antibody in parallel

• Protocol parameters:

  • For Western blots: Use 2-5 μg of blocking peptide per 1 μg of antibody

  • For IHC: Higher ratios (10:1) may be needed for complete blocking

  • Include gradient blocking to demonstrate concentration-dependent inhibition

  • Document reduction or elimination of signal as evidence of specificity

• Controls and interpretation:

  • Include peptides from unrelated proteins as negative controls

  • Use peptides from related ABC transporters to assess cross-reactivity

  • True specific binding should show significant signal reduction with specific peptide but not with control peptides

  • Partial blocking may indicate antibody recognizes multiple epitopes

• Reporting standards:

  • Document exact peptide sequences used for blocking

  • Report peptide concentrations and incubation conditions

  • Include images of both blocked and unblocked samples

  • Quantify the percentage of signal reduction when possible

Several vendors offer ABCC13 neutralizing peptides specifically designed for their antibodies, facilitating proper validation .

How can ABCC13 antibodies be used to investigate its potential role in cancer research?

While ABCC13's functional significance remains under investigation, several approaches using antibodies can help explore its potential role in cancer:

• Expression profiling in cancer tissues:

  • Screen tissue microarrays from various cancer types using IHC

  • Compare ABCC13 expression between matched tumor and normal tissues

  • Correlate expression with clinical parameters and outcomes

  • Examine different cancer stages to assess progression-related changes

• Cellular localization studies:

  • Use immunofluorescence to determine subcellular distribution in cancer cells

  • Investigate potential relocalization during malignant transformation

  • Co-localize with other cancer-relevant proteins

  • Examine changes in localization following treatment with chemotherapeutics

• Potential prognostic marker assessment:

  • Quantitative analysis of expression levels across patient cohorts

  • Correlation with treatment response and survival outcomes

  • Comparison with established cancer biomarkers

  • Multivariate analysis to assess independent prognostic value

• Functional investigation approaches:

  • Combine antibody detection with knockdown/overexpression studies

  • Monitor expression changes in response to cancer-relevant signaling pathways

  • Investigate relationship with other ABC transporters implicated in drug resistance

  • Correlate with cancer stem cell markers in relevant models

While ABCC13 itself is a pseudogene lacking transport function , its expression pattern in cancer tissues may still provide valuable insights, similar to how other ABC transporters have been investigated as potential tumor antigens .

What methodological approaches should be used when investigating ABCC13 in relation to other ABC transporters?

To effectively study ABCC13 in the context of other ABC transporters:

• Comparative expression analysis:

  • Design multiplexed detection systems for simultaneous analysis

  • Use carefully validated antibodies specific to each ABC transporter

  • Compare expression patterns across tissue panels and disease states

  • Quantify relative expression levels using calibrated detection systems

• Cross-reactivity prevention strategies:

  • Select antibodies targeting non-conserved regions of ABCC13

  • Test specificity using overexpression systems for individual transporters

  • Include appropriate knockout/knockdown controls when available

  • Consider epitope mapping to identify unique recognition sites

• Functional correlation studies:

  • Compare ABCC13 expression with functional ABC transporters (ABCC1, ABCC2, ABCC3, ABCC6)

  • Investigate potential regulatory relationships between family members

  • Assess compensation mechanisms in response to manipulation of individual transporters

  • Evaluate co-regulation patterns in response to physiological stimuli

• Phylogenetic and evolutionary context:

  • Compare expression across species with functional versus pseudogene status

  • Investigate tissue-specific expression patterns across evolutionary lineages

  • Use antibodies validated for cross-species detection when appropriate

  • Correlate protein expression with genomic and transcriptomic analyses

The remarkable similarity between ABCC13's putative membrane-spanning domains and those of ABCC1, ABCC2, ABCC3, and ABCC6 necessitates careful experimental design to distinguish between these related proteins.

How might researchers effectively use ABCC13 antibodies in developmental biology studies?

Given ABCC13's differential expression during development, particularly in hematopoietic tissues , antibody-based approaches for developmental studies include:

• Temporal expression mapping:

  • Track ABCC13 expression across developmental stages using immunohistochemistry

  • Compare with known developmental markers

  • Use whole-mount immunostaining for embryonic studies

  • Quantify expression changes during key developmental transitions

• Lineage tracing approaches:

  • Combine ABCC13 detection with lineage-specific markers

  • Track expression during differentiation of specific cell types

  • Use flow cytometry for quantitative assessment in developing tissues

  • Correlate with functional developmental outcomes

• Comparative embryology studies:

  • Compare expression patterns across model organisms

  • Use antibodies validated for cross-species reactivity when appropriate

  • Correlate protein expression with genetic manipulation of developmental pathways

  • Investigate potential functional redundancy with other ABC transporters

• Mechanistic developmental studies:

  • Combine antibody detection with pathway inhibitors

  • Monitor expression in response to developmental signaling molecules

  • Investigate potential roles in cell migration, proliferation, or differentiation

  • Correlate with developmental phenotypes in genetic models

• Tissue-specific developmental analysis:

  • Focus on fetal liver as a primary site of expression

  • Compare with bone marrow development

  • Investigate potential roles in embryonic hematopoiesis

  • Examine relationship with hematopoietic stem cell markers

The documented high expression in fetal liver and its decrease during hematopoietic cell differentiation make ABCC13 a potentially interesting target for developmental biology investigations.

What approaches can be used to resolve contradictory findings when using different ABCC13 antibodies?

When faced with contradictory results from different ABCC13 antibodies, researchers should implement a systematic validation approach:

• Comprehensive epitope analysis:

  • Map the exact epitopes recognized by each antibody

  • Assess potential overlap or differences in target regions

  • Consider how epitope location might affect detection in different contexts

  • Evaluate whether discrepancies might reflect detection of different isoforms

• Multi-platform validation:

  • Compare results across multiple detection methods (WB, IHC, IF, ELISA)

  • Employ orthogonal techniques (mass spectrometry, RNA-seq)

  • Use genetic approaches (knockout/knockdown) to verify specificity

  • Correlate protein detection with mRNA expression

• Side-by-side comparison protocol:

  • Test all antibodies simultaneously under identical conditions

  • Standardize sample preparation, blocking, and detection methods

  • Include multiple positive and negative controls

  • Document all experimental parameters for proper comparison

• Isoform-specific analysis:

  • Determine if discrepancies reflect detection of different ABCC13 isoforms

  • Use recombinant expression of specific isoforms as references

  • Design experiments to distinguish between alternative splicing variants

  • Consider the five documented isoforms of ABCC13 in your analysis

• Technical optimization:

  • Titrate each antibody to optimal working concentration

  • Test multiple fixation and antigen retrieval methods

  • Evaluate sensitivity to sample preparation methods

  • Consider batch effects and storage stability of each antibody

By systematically addressing these factors, researchers can better understand and resolve contradictory findings, ultimately determining which antibody provides the most reliable results for their specific research question.

How can researchers effectively design experiments to study the regulation of ABCC13 expression?

To investigate mechanisms regulating ABCC13 expression:

• Promoter analysis approaches:

  • Use chromatin immunoprecipitation (ChIP) to identify transcription factors binding to the ABCC13 promoter

  • Design reporter assays with ABCC13 promoter fragments

  • Identify regulatory elements through mutation analysis

  • Correlate transcription factor expression with ABCC13 levels using antibody detection

• Epigenetic regulation studies:

  • Investigate DNA methylation patterns in the ABCC13 promoter region

  • Examine histone modifications associated with active/inactive ABCC13 expression

  • Test effects of epigenetic modifiers on ABCC13 expression

  • Use antibody detection to quantify expression changes following epigenetic manipulation

• Developmental regulation assessment:

  • Track expression changes during differentiation of relevant cell types

  • Identify developmental signaling pathways influencing ABCC13 expression

  • Compare expression patterns in embryonic versus adult tissues

  • Document the temporal regulation during hematopoietic development

• Stress and environmental response:

  • Monitor expression changes in response to cellular stress conditions

  • Test effects of hypoxia, oxidative stress, and nutrient deprivation

  • Examine potential regulation by inflammatory mediators

  • Quantify expression following exposure to xenobiotics

• Post-transcriptional regulation:

  • Investigate potential microRNA regulation of ABCC13 transcripts

  • Analyze RNA binding protein interactions with ABCC13 mRNA

  • Assess transcript stability under different conditions

  • Compare protein and mRNA levels to identify translational regulation

The documented response of ABCC13 to specific hormones—induction by gibberellic acid and downregulation by naphthalene acetic acid, abscisic acid, and zeatin in Arabidopsis —suggests potential conserved regulatory mechanisms that could be explored in mammalian systems.

What considerations should researchers keep in mind when using ABCC13 antibodies in complex biological samples like serum or tissue lysates?

Working with ABCC13 antibodies in complex biological samples requires special attention to:

• Sample preparation optimization:

  • For tissue lysates: Use detergent combinations optimized for membrane proteins

  • For serum: Consider depletion of abundant proteins to enhance detection sensitivity

  • Standardize protein extraction protocols for consistency

  • Include protease and phosphatase inhibitors to preserve protein integrity

• Pre-analytical variable control:

  • Document sample collection, processing, and storage conditions

  • Standardize freeze-thaw cycles to minimize degradation

  • Consider time-dependent changes in protein stability

  • Normalize loading based on total protein rather than single housekeeping genes

• Cross-reactivity mitigation:

  • Increase blocking stringency (5% BSA or 5% milk, extended incubation)

  • Include additional washing steps with higher detergent concentrations

  • Consider pre-adsorption of antibodies with common cross-reactive proteins

  • Use antibody dilutions at the higher end of the recommended range

• Signal verification approaches:

  • Confirm specificity with multiple antibodies targeting different epitopes

  • Include peptide competition controls specific to the complex sample type

  • Compare detection across multiple technical platforms

  • Verify signal correlation with known ABCC13 expression patterns

• Matrix effect consideration:

  • Assess potential interference from matrix components

  • Include matrix-matched controls

  • Evaluate signal recovery by spiking known quantities of recombinant protein

  • Consider sample dilution series to identify optimal working range

When working with human serum samples, researchers should note that antibody detection systems have been successfully deployed in complex matrices like serum for other applications , providing methodological guidance that can be adapted for ABCC13 studies.